Laurene Wang, PhD, Founder and Chief Executive Officer
Dr. Laurene Wang founded AimMax Therapeutics, Inc. in 2016 with the goal of building AimMax to a global company, aiming for the maximal delivery of therapeutics to enhance global health. Dr. Wang is an entrepreneur and drug developer with over 30 years of hands-on, management and leadership experiences in the multidisciplinary areas of pharmaceutical research, development and regulations. She received a PhD degree from the University of California, San Francisco under world renowned leaders in clinical pharmacology and pharmaceutics/drug delivery. Her broad experiences were gained from employment and growing positions with two major Pharmas (Burroughs Wellcome, Glaxo Wellcome/GlaxoSmithKline) and two start-up companies (Triangle Pharmaceuticals/Gilead Sciences, DarPharma), contributing to the discovery, in-licensing, development and regulatory approval of more than 10 drugs currently on the global market. She has also worked at the US FDA as a reviewer and the Clinical Center of the NIH; and international clinical CROs and regulatory consulting firms. She has authored more than 45 peer-reviewed publications and served as an invited speaker to numerous scientific, regulatory and drug development conferences. Dr. Wang was the principal investigators and consultants to several NIH grants/contracts and SBIR grants, and has served as the NIH research grant or SBIR grant reviewer.
On the business side, Dr. Wang has had experience with running a start-up company, DarPharma Inc., spun off the Univ. of North Carolina, Chapel Hill, by serving as the Chief Operating Officer and Executive Vice President for Preclinical and Clinical Development at company’s inception, assisting the CEO with fund raising, business and administrative operations along with drug development functions. Subsequently, she founded a consulting company, INDAPharma, LLC, as well as a personnel resources company, PDM Resources, Inc., in North Carolina, providing turn-key or a la carte contract services to close to 80 pharma and biotech companies at various stages of development for small (chemical) molecules or large molecules (proteins and monoclonal antibodies) in various therapeutic areas. Throughout her career, Dr. Wang has earned the reputation of being credible, focused, resourceful and thinking out of box, a leader who is determined and will do the right things to achieve success in the most efficient manner. She is being sought by several global investors or pharma partners to start up or lead pharma or biotech companies, which prompted the founding of AimMax Therapeutics, Inc.